Management of cutaneous T-cell lymphoma: The future is here.
Wood
G S
GS
Division of Dermatology, University of Wisconsin, Madison, USA.
D000970:Antineoplastic Agents / Q000008:administration & dosage; D016207:Cytokines / Q000096:biosynthesis*; D003602:Cytotoxicity, Immunologic; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage; D007694:Killer Cells, Natural / Q000276:immunology; D017893:Photopheresis; D011994:Recombinant Proteins; D012751:Sezary Syndrome / Q000175:diagnosis / Q000276:immunology / Q000628:therapy*; D012878:Skin Neoplasms / Q000175:diagnosis / Q000276:immunology / Q000628:therapy*; D018418:Th2 Cells / Q000276:immunology* / Q000378:metabolism
D000970:Antineoplastic Agents; D016207:Cytokines; D007155:Immunologic Factors; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins